ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma

CNS Oncology Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/1RPZujx
via IFTTT